MDWD - MediWound rise on MWPC005 melanoma skin cancer study launch

MediWound (MDWD) shares up nearly 8% premarket after announcing the initiation of a new clinical development program to evaluate its drug product candidate MWPC005 in patients with non-melanoma skin cancer.The company recently submitted a protocol to the FDA for a phase I/II clinical study of MWPC005 for the treatment of basal cell carcinoma ((BCC)) and is preparing to initiate this study in the United States in Q2 2021.A phase II investigator-initiated trial of MWPC005 in non-melanoma skin cancer will be conducted in parallel at the Soroka Medical Center in Israel, with data from both studies expected by the end of 2021.The phase I/II open-label, randomized clinical study of MWPC005 in BCC is designed to evaluate safety and tolerability using different schedules of administration, as well as provide a preliminary evaluation of efficacy as measured by the percentage of target lesion with complete histological clearance.The phase II investigator-initiated trial is an open-label study, designed to evaluate the

For further details see:

MediWound rise on MWPC005 melanoma skin cancer study launch